🇺🇸 FDA
Pipeline program

ORMD-0801 (qd)

ORA-D-012

Phase 3 small_molecule completed

Quick answer

ORMD-0801 (qd) for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at ORAMED PHARMACEUTICALS INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
ORAMED PHARMACEUTICALS INC.
Indication
Type 2 Diabetes Mellitus
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials